Clinical trial Recruiting at 2 sites Interventional Ages 18 to 80

Greater Occipital Nerve Block for Migraine with Medication Overuse Headache

Run by Mahidol University · NCT07568496 · Data updated 2026-11-12

This study will test whether a nerve block using lidocaine and methylprednisolone can help people with migraine who overuse medications to reduce withdrawal headaches during detoxification.

Quick facts

Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment130 (estimated)
SponsorMahidol University
Academic / other
Locations3 sites (Bangkok, Bangkok and 2 other locations)
StatusRecruiting
StartedMay 12, 2026
Main results expectedNovember 1, 2028
Study endsNovember 1, 2028
Registry record updatedOctober 8, 2026
Trial IDNCT07568496 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women with migraine and medication overuse headache who meet ICHD-3 criteria and have no contraindicating conditions.

Probably not a fit

Patients with non-migraine headaches, certain medical contraindications, or those on CGRP therapies or botulinum toxin may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study evaluates the efficacy of a greater occipital nerve block (GONB) as a bridging therapy for detoxification in patients with migraine and medication overuse headache (MOH). Participants will receive either lidocaine with methylprednisolone or placebo, as part of a detoxification plan across three Thai headache centers from February 2026 to January 2028. The trial targets adults diagnosed with MOH per ICHD-3 criteria, excluding those with other headache types, certain medical histories, or current CGRP/botulinum toxin therapies. Outcomes will inform whether GONB can reduce withdrawal-related headache and support MOH treatment strategies. The research is sponsored by Mahidol University with collaborators from three universities.

Why it matters

Potential benefit: If successful, GONB could become a viable option to ease detoxification and reduce headache days during MOH treatment.

How similar studies have gone: Prior data support GONB for chronic migraine, but this is a placebo-controlled evaluation specifically for MOH.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients who have a diagnosis of migraine with medication overuse headache according to ICHD-3 criteria confirmed by a neurologist
* Female patients will be screened for pregnancy planning and married female patients must undergo a urine pregnancy test

Exclusion Criteria:

* Patients who have other types of headache disorders other than migraine
* Patients who have a previous history of allergy to corticosteroid or lidocaine
* Patients who had previous skull surgery
* Pregnant women
* Patients with a history of uncontrolled depression, or psychosis
* Patients who get or plan to get CGRP-targeted therapies or botulinum toxin injection
* Patients with an increased risk of bleeding or underlying bleeding disorders

Where it's running

  • Faculty of Medicine Siriraj Hospital, Mahidol University
    Bangkok, Bangkok, Thailand
    Recruiting
  • Faculty of Medicine, Prince of Songkla University
    Hat Yai, Changwat Songkhla, Thailand
    Recruiting
  • Faculty of Medicine, Chiang Mai University
    Chiang Mai, Chiang Mai, Thailand
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.